- Home
- RYTM vs AXSM Comparison
RYTM vs AXSM Comparison
Compare RYTM & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | AXSM |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | 816 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.4B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RYTM | AXSM |
|---|---|---|
| Price | $111.98 | $153.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | $127.31 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 966.4K | 471.7K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $174,334,000.00 | ★ $561,263,000.00 |
| Revenue This Year | $47.34 | $66.20 |
| Revenue Next Year | $57.18 | $57.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 54.92 | ★ 65.83 |
| 52 Week Low | $45.91 | $75.56 |
| 52 Week High | $122.20 | $152.94 |
Technical Indicators
Market Signals| Indicator | RYTM | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 64.08 |
| Support Level | $109.99 | $145.07 |
| Resistance Level | $115.05 | $149.13 |
| Average True Range (ATR) | 5.20 | 4.48 |
| MACD | 0.60 | -0.35 |
| Stochastic Oscillator | 53.93 | 94.96 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.